Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MVT 2163

Next Previous
Drug Profile

MVT 2163

Alternative Names: 89Zr-DFO-HuMab-5B1; 89Zr-HuMab 5B1; MVT-2163; PET Imaging agent - MabVax Therapeutics; Radiolabelled 5B1 diabody (sLeA); Zirconium anti-sialyl Lewisa imaging agent - MabVax

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HonorHealth; MabVax Therapeutics
  • Developer BioNTech; MabVax Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Drug conjugates; Imaging agents; Immunoconjugates; Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
  • Mechanism of Action Diagnostic imaging enhancers; Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Bladder cancer; Colorectal cancer; Pancreatic cancer; Small cell lung cancer

Most Recent Events

  • 28 Feb 2025 No recent reports of development identified for phase-I development in Pancreatic-cancer(Diagnosis, Late-stage disease, Metastatic disease) in USA (IV)
  • 27 Jan 2025 Memorial Sloan Kettering Cancer Center in collaboration with BioNTech completes a phase I trial in Pancreatic cancer (Diagnosis, Late-stage disease, Metastatic disease) in USA (IV) (NCT04883775)
  • 28 Jun 2024 No recent reports of development identified for phase-I development in Pancreatic-cancer(Diagnosis, Late-stage disease, Metastatic disease) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top